OBJECTIVE: @entity16 due to transient @entity2806 is a potential complication of cardiovascular surgery. The neuroprotective effect of @entity1760 , when given subcutaneously before the @entity63 , was assessed in a @entity35 model of transient global @entity2806 . METHODS: Thirty-six male @entity35 albino @entity35 were included to this randomized, controlled, prospective study. In 24 animals, @entity63 was induced with four-vessel occlusion technique with the duration of 15 min. @entity2400 was given 600 mg/kg subcutaneously 48 h before the procedure in group 1 (n = 12). Similar volume of saline solution was used in animals of control group (group 2, n = 12). The animals in group 3 (sham group, n = 12) were anesthetized and subjected to operative dissections without @entity432 . Physiological parameters and somatosensory evoked-potentials (SEP) were monitored in animals before @entity63 , during @entity63 and in the first 30 min of reperfusion. Their neurological outcome had been clinically evaluated and scored up to 4 days postischemia. The intergroup differences were compared. Then the animals were sacrificed and their brains were processed for histopathological examination. RESULTS: In group 3, SEP amplitudes did not change during the procedures, and all animals recovered without @entity51 . At the end of @entity63 period, the average amplitude was reduced to 5 +/- 3% of the baseline in all @entity63 animals. This was followed by a gradual return to 87 +/- 10% and 83 +/- 8% of the initial amplitude after 30 min of reperfusion in group 1 and group 2, respectively (P > 0.05). The average neurological score was significantly higher in group 1 than in group 2 at 48, 72 and 96 h after the @entity63 insult (P < 0.05). Histological observations were clearly correlated with the neurological findings. CONCLUSION: The results suggest that subcutaneous @entity2400 reduces @entity131 and preserves neurologic function when given two days before the transient global @entity63 in @entity35 .

Neuroprotective effects of preischemia subcutaneous magnesium sulfate in transient XXXX .

@entity131 :: ('MESH:D001930', 'Disease') :: ['cerebral injury'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic', 'ischemia'] @entity16 :: ('MESH:D009422', 'Disease') :: ['Neurological injury'] @entity2400 :: ('CHEBI:32599', 'Chemical') :: ['MgSO4'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurologic deficits'] @entity432 :: ('MESH:D001157', 'Disease') :: ['vascular occlusion'] @entity35 :: ('10116', 'Species') :: ['rat', 'Wistar', 'rats'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity2806 :: (MESH:D002545,Disease) :: ['cerebral ischemia']
